New BRCA-targeting drug could treat advanced prostate cancer
Talazoparib delayed disease progression in Phase II trial
Read More
Tag: BRCA
Researchers identify new drug class with potential in BRCA-mutated tumours
POLQ inhibitors could be used to kill PARP inhibitor-resistant cancer cells
Read More
Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
Trial success for Lynparza in prostate cancer
The treatment is the only PARP inhibitor with positive Phase III results in four different cancer types – ovarian, breast, pancreatic and prostate.
Read More
Myriad, AstraZeneca and MSD expand collaboration
The expansion will use BRACAnalysis CDx to identify germline BRCA mutations.
Read More
Lynparza gets FDA approval for ovarian cancer
Lynparza has been approved in the US for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer.
Read More
NICE says no to expanding use of AZ/MSD’s Lynparza
The National Institute for Health and Care Excellence has ruled against expanding use of AstraZeneca/MSD’s Lynparza to a wider patient population with ovarian cancer.
Read More
Four new medicines cleared for use on NHS Scotland
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read More
AZ/MSD pursue wider indication for Lynparza on trial success
AstraZeneca and MSD have unveiled trial results showing that Lynparza significantly extended the time patients with ovarian cancer lived without their disease worsening in the first-line maintenance setting, which could significantly expand the drug’s reach.
Read More
Pfizer files PARP inhibitor for breast cancer in US, EU
Regulators on both sides of the Atlantic have accepted for review Pfizer’s PARP inhibitor talazoparib as a treatment for women with a hereditary BRCA mutation.
Read More
EU regulators widen Lynparza’s reach
European regulators have approved a tablet formulation and new dosing regimen for AstraZeneca and MSD’s Lynparza to treat a wider range of patients with ovarian cancer.
Read More
Research backs blanket screening for breast, ovarian cancer mutations
Research led by Queen Mary University of London has concluded that whole-population testing for mutations linked with a higher risk of breast and ovarian cancer is cost-effective.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
